Skip to content

Study · Not a test of the peptide alone · 2022

2 results

Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.

Habibullah MM, Mohan S, Syed NK, Makeen HA, Jamal QMS, Alothaid H, Bantun F, Alhazmi A, Hakamy A, Kaabi YA, Samlan G, Lohani M, Thangavel N, Al-Kasim MA

Drug design, development and therapy27 Jun 2022Cited by 8 (Europe PMC)

PMID35783198 (opens in a new tab)PMCIDPMC9249349 (opens in a new tab)DOI10.2147/dddt.s367586 (opens in a new tab)PepBankPUB-35783198
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, HGH fragment 176-191 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking HGH fragment 176-191.

  1. 01LabNot a test of HGH fragment 176-191 aloneIn vitro (cell-free)Other

    In photon correlation spectroscopy, dual-loaded hGH fragment and doxorubicin Chitosan nanoparticles had favorable particle size, polydispersity index and zeta potential.

    In plain wordsIn lab tests, nanoparticles carrying hGH fragment and doxorubicin had favorable physical characteristics.

    Peptide
    HGH fragment 176-191
    Outcome
    Not applicableNanoparticle physicochemical characteristics
    Study

    n: not reported in source

    Dual-loaded Chitosan nanoparticles
    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    photon correlation spectroscopy revealed that the synthesized dual-loaded Chitosan nanoparticles possess clinically favorable particle size, polydispersity index, as well as zeta potential.

    In this study, HGH fragment 176-191 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking HGH fragment 176-191.

  2. 02Computer modelNot a test of HGH fragment 176-191 aloneIn silicoMechanism

    In molecular docking, adding hGH fragment to doxorubicin-loaded Chitosan nanoparticles was predicted to enhance doxorubicin binding to multiple breast cancer targets.

    In plain wordsIn computer models, adding hGH fragment to doxorubicin-loaded nanoparticles was predicted to enhance doxorubicin binding compared with nanoparticles without the fragment.

    Peptide
    HGH fragment 176-191
    Outcome
    IncreasePredicted doxorubicin binding
    Study

    n: not reported in source

    Molecular docking simulations of breast cancer protein targets
    Comparator
    Doxorubicin-loaded Chitosan nanoparticles without hGH fragment
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    In silico analysis suggested that addition of the hGH fragment to doxorubicin-loaded Chitosan nanoparticles can enhance doxorubicin binding to multiple breast cancer protein targets

    In this study, HGH fragment 176-191 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking HGH fragment 176-191.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.